Peter Herhaus

First Experience with Chemokine Receptor CXCR4–Targeted PET Imaging of Patients with Solid Cancers

Tibor Vág, Peter Herhaus, Matthias Eiber et al. · Journal of Nuclear Medicine · 2016 · 146 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Martin Dreyling, Jeanette K. Doorduijn, Eva Giné et al. · The Lancet · 2024 · 136 citations · Full text

Medicine, Hematology, Oncology +10

Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics

Stefan Habringer, Constantin Lapa, Peter Herhaus et al. · Theranostics · 2017 · 105 citations · Full text

Medicine, Oncology, Pharmacology +17

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial

Paul J. Bröckelmann, Ina Bühnen, Karolin Trautmann‐Grill et al. · Journal of Clinical Oncology · 2022 · 92 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Side Effects of CXC-Chemokine Receptor 4–Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation

Sabine Maurer, Peter Herhaus, Romina Lippenmeyer et al. · Journal of Nuclear Medicine · 2019 · 69 citations · Full text

Medicine, Oncology, Pharmacology +17